Agilent Technologies Inc. has introduced SurePrint G3 CGH+SNP cancer catalog microarrays, addressing the growing need of researchers to detect both copy number and copy-neutral aberrations in cancer ...

Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...

Roche NimbleGen, Inc. has launched NimbleGen Comparative Genomic Hybridization (CGH) microarrays in a 12x135K format for analysis of DNA copy number variation. NimbleGen CGH 12x135K arrays will allow ...

In addition to the surprising revelation that our chromosomes harbor fewer genes than originally predicted, the Human Genome Project also unveiled that all individuals share approximately 99.9% of ...

A comprehensive genomic analysis of single cells is needed for numerous scenarios in tumor genetics, clinical diagnostics and forensic application. PCR protocols were developed which allow an unbiased ...

Comparative genomic hybridization (CGH) has been used for a genome-wide screening of genetic imbalances in tumours. As CGH to chromosomes is technically difficult and yields only limited resolution, ...

Multicenter Phase II Trial of Immunotherapy With the Humanized Anti-CD22 Antibody, Epratuzumab, in Combination With Rituximab, in Refractory or Recurrent Non-Hodgkin's Lymphoma Genomic losses were ...

Bioinformatics-analysis division is a division of CD Genomics, which provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.

OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch® 3D ...